Insider · CIK 0001385496
Jon P Stonehouse
ceopresidentofficerdirector
Files at BCRX (BIOCRYST PHARMACEUTICALS INC), MTSR (Metsera, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +644 | $9.70 | $6,247 | 1,340,419 | 40 d ago |
| Apr 28, 2025 | MTSR Metsera, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +47,730 | $19.81 | $946k | 47,730 | Apr 30, 2025 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +362,100 | $0.00 | $0 | 1,463,119 | Dec 23, 2024 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | FTax withholding Common Stock | -14,010 | $7.39 | $104k | 1,449,109 | Dec 23, 2024 |
| Dec 20, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | GGift Common Stock | -20,000 | $0.00 | $0 | 1,429,109 | Dec 23, 2024 |
| Dec 20, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | GGift Common Stockindirect: By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust | +10,000 | $0.00 | $0 | 30,000 | Dec 23, 2024 |
| Dec 20, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | GGift Common Stockindirect: By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust | +10,000 | $0.00 | $0 | 30,000 | Dec 23, 2024 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Emp. Stock Option (Right to Buy)derivative | +750,250 | $0.00 | $0 | 750,250 | Dec 23, 2024 |
| Dec 14, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | FTax withholding Common Stock | -27,525 | $7.53 | $207k | 1,101,019 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.